SESSION VII: CHRONIC LYMPHOCYTIC LEUKEMIA

Session Chairs: John Seymour, MBBS, FRACP, PhD and Lindsay Roeker, MD

Data From NGS What to Do With Additional Abnormalities Found at Diagnosis | Lydia Scarfò, MD | Università Vita-Salute San Raffaele, Milan, Italy

Optimizing Treatment Outcomes With Combination Therapies, Optimal Sequencing, and MRD-Guided Treatment Duration | Paula Cramer, MD | University of Cologne, Cologne, Germany

Debate: Debate: Progression on cBTKI: Change to Non-Covalent BTKi | Jeff P. Sharman, MD | Willamette Valley Cancer Institute-Sarah Cannon, Eugene, Oregon, USA

Debate: Progression on cBTKi: Change to Ven-Based Therapy | Gianluca Gaidano, MD, PhD | University of Eastern Piedmont, Novara, Italy

Interesting Clinical Case(s) | Mazyar Shadman, MD, MPH | Fred Hutchinson Cancer Research Center, Seattle, Washington, USA

New Targets/Drugs on the Horizon | Meghan C. Thompson, MD | Memorial Sloan Kettering Cancer Center, New York, New York, USA

Oral Abstract | CLL-563: Bexobrutideg (NX-5948), a Novel Bruton’s Tyrosine Kinase Degrader, Demonstrates Rapid and Durable Clinical Responses in Relapsed/Refractory Chronic Lymphocytic Leukemia: Updated Findings From an Ongoing Phase 1a Study | Nirav N. Shah, MD | Medical College of Wisconsin, Milwaukee, Wisconsin, USA